Bevacizumab (Avastin): Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
Visual
(Updated category= to treatment_category= in TreatmentInfo template)
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{TreatmentInfo
{{TreatmentInfo
|drug_name=Bevacizumab (Avastin)
|drug_name=Procarbazine
|FDA_approval=Yes, for recurrent glioblastoma
|FDA_approval=Yes
|used_for=Glioblastoma
|used_for=Glioblastoma
|clinical_trial_phase=Phase III
|clinical_trial_phase=Not specified
|common_side_effects=Hypertension, proteinuria, and hemorrhage
|common_side_effects=Hematological toxicity, nausea, and neurological effects
|OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months
|OS_with=Not specified
|usefulness_rating=4
|usefulness_rating=3
|notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.
|notes=Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.
|treatment_category=Other Chemotherapy and Cancer Drugs
|treatment_category=Other Chemotherapy and Cancer Drugs
|toxicity_level=3
|toxicity_level=4
|toxicity_explanation=Bevacizumab has an intermediate level of toxicity. Although it is a powerful medication against glioblastoma, it can have serious side effects including high blood pressure (hypertension), presence of excess proteins in the urine (proteinuria), and bleeding (hemorrhage). These side effects can impact your general health and daily activities. Therefore, this treatment needs regular monitoring by your health care provider and should be used with caution.
|toxicity_explanation=The drug Procarbazine is considered quite toxic. This rating is based on the common side effects like hematological toxicity, which refers to potential harm to your blood cells, nausea, and neurological effects such as headache or dizziness. These side effects are relatively common and could significantly affect your day-to-day life. Remember, all treatments come with potential risks, and it's important to discuss these with your doctor.
|book_text=The most notable development in drug combinations has been the addition of the anti-
|book_text=Temodar has also been combined with procarbazine (64). While the report of that study
angiogenic drug, Avastin (also known as bevacizumab), to the standard Stupp protocol.
did not include the PFS-6 statistic, it did report an unusually high percentage of tumor
As will be discussed later, Avastin has FDA approval for the treatment of glioblastomas
regressions, suggesting that this combination might be effective.
that have recurred or progressed after initial treatment. Several clinical trials have now
|overview=Procarbazine is an FDA-approved chemotherapy drug primarily used for treating glioblastoma, known for its effectiveness when combined with Temodar, as evidenced by a high percentage of tumor regressions. However, it carries a toxicity level of 4, with common side effects including hematological toxicity, nausea, and neurological effects that can significantly impact daily life.}}
investigated its combination with the gold standard Temodar protocol.
 
Recently, there have been two large randomized phase III clinical trials comparing
 
the Stupp protocol and the Stupp protocol + Avastin, for newly diagnosed patients. In the
first of these (70), known as the AVAglio trial, median PFS was 10.6 months for those
receiving Avastin versus 6.2 months for those receiving only the Stupp protocol, a
statistically significant difference. However, median overall survival was not different
(16.8 months vs. 16.7 months). It should be noted that patients in the control group
 
 
typically received Avastin after tumor progression occurred, so that the comparison was
 
really between Avastin given early versus Avastin given only after recurrence. Additional
results were that 72% of the Avastin group was alive at one year, compared to 66% of the
control group, while two year survival was 34% vs. 30%.
 
In the second of these large trials (71), conducted by the RTOG consortium, the design
was essentially similar to the AVAglio trial, as were the results. Median PFS was 10
months for those receiving Avastin vs. 7.3 months for the control group (again statistically
significant), while median overall survival was 15.7 months for the Avastin group
compared to 16.1 months for the control, a nonsignificant difference.
 
The best interpretation of these results is that patients have a longer time without tumor
progression, and presumably a better quality of life, when Avastin is used as part of the
initial treatment. However, there is no benefit for overall survival, when compared to
withholding Avastin until recurrence is detected. An additional feature of the results, not
emphasized by the authors of the reports, is that the overall survival times were not
notably better, and in many cases worse, than those obtained when the Stupp protocol is
combined with various other treatment agents.
}}

Latest revision as of 01:22, 18 January 2025

Property Information
Drug Name Procarbazine
Overview Procarbazine is an FDA-approved chemotherapy drug primarily used for treating glioblastoma, known for its effectiveness when combined with Temodar, as evidenced by a high percentage of tumor regressions. However, it carries a toxicity level of 4, with common side effects including hematological toxicity, nausea, and neurological effects that can significantly impact daily life.
FDA Approval Yes
Used for Glioblastoma
Clinical Trial Phase Not specified
Clinical Trial Explanation Not specified
Common Side Effects Hematological toxicity, nausea, and neurological effects
OS without Not specified
OS with Not specified
PFS without Not specified
PFS with Not specified
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level 4
Toxicity Explanation The drug Procarbazine is considered quite toxic. This rating is based on the common side effects like hematological toxicity, which refers to potential harm to your blood cells, nausea, and neurological effects such as headache or dizziness. These side effects are relatively common and could significantly affect your day-to-day life. Remember, all treatments come with potential risks, and it's important to discuss these with your doctor.

Notes: Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.


From Ben Williams Book: Temodar has also been combined with procarbazine (64). While the report of that study did not include the PFS-6 statistic, it did report an unusually high percentage of tumor regressions, suggesting that this combination might be effective.Property "Has original text" (as page type) with input value "Temodar has also been combined with procarbazine (64). While the report of that study</br>did not include the PFS-6 statistic, it did report an unusually high percentage of tumor</br>regressions, suggesting that this combination might be effective." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.

Loading comments...
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Bevacizumab_(Avastin)&oldid=94204"